Abu Dhabi Pioneers Collaborative Approach to Responsible AI in Healthcare at Health Leaders Roundtable
ABU DHABI, UAE, April 24, 2025 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, convened senior international government officials at the Health Leaders Roundtable to shape a Declaration on AI governance principles for healthcare. Held on the sidelines of Abu Dhabi Global Health Week (ADGHW), it considered the challenges and opportunities in unlocking the potential of artificial intelligence (AI), and explored key principles in the governance of AI in healthcare.
Hosted together with PwC Middle East, findings from the roundtable will inform the development of a collaborative approach that will serve as a reference for governments, health systems, and innovators to ensure that AI's integration into healthcare systems is transparent, responsible, and inclusive.
His Excellency Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, added: "AI is not tomorrow's technology, it is today's reality. While many of us are adapting to its rise, our children will grow up with it as the norm. That's why the decisions we make today, around ethics, equity, and safety, must be made together. Through this declaration, we will establish a globally accessible guideline that extends beyond borders and commercial interests. This document is a call to action for governments, innovators, and healthcare leaders everywhere."
The forthcoming Declaration on governance principles for AI in healthcare will outline guiding principles for responsible AI deployment to improve health outcomes and protect patient rights. Designed as a globally accessible resource, the declaration will inspire unified governance and serve as a trusted reference for stakeholders worldwide.
In her opening remarks at the Roundtable, Her Excellency Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, stated: "AI has extraordinary potential in healthcare. It is already transforming how we deliver care, how we diagnose, and how we discover. But with great power comes great responsibility. In Abu Dhabi, we are harnessing AI as our engine and policy as our platform, turning data into life-saving insight, and insight into meaningful action. Our vision is to deliver healthcare that is precise, proactive, and personal and to do so in a way that puts people, not technology, at the centre."
During the Roundtable, participants emphasised the need for agile legal and regulatory frameworks to enable the safe and ethical application of AI in healthcare, while enabling innovation. With an emphasis on the need for a human-centred approach, discussions explored key themes including standardisation of data, data privacy and trust, skills development and community engagement.
Key insights from the Roundtable highlight the need for:
The Health Leaders Roundtable brought together a distinguished group of local and international voices, including government officials, AI experts, healthcare executives, and multilateral organisations, to explore the shared principles and practices needed to deploy AI responsibly, effectively, and equitably.
These themes build on Abu Dhabi's rapidly advancing AI ecosystem, which in the field of health, is taking billions of data points, and turning them into life-changing insights.
Supporting the Emirates's approach is the Global AI Healthcare Academy, launched by DoH, which equips healthcare professionals worldwide with theoretical knowledge and hands-on training needed to implement AI technologies effectively, setting a global standard for capacity building. In addition, Malaffi - the region's first Health Information Exchange - provides secure, real-time access to patient data across both public and private healthcare providers. This seamless data integration is crucial for enabling AI tools to be deployed safely, efficiently, and at scale.
ADGHW is a major government initiative from DoH, and serves as a platform for innovation and collaboration under the 2025 theme 'Towards Longevity: Redefining Health and Well-being.' By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
7 hours ago
- Korea Herald
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: " I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. Press contact
Korea Herald
16 hours ago
- Korea Herald
Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market
KUALA LUMPUR, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed a Memorandum of Understanding (MOU) with ASK Intercity Co., Ltd. for the sales and distribution of Physta ® Tongkat Ali, Biotropics' proprietary standardized extract, in the Japanese market. The MOU signing took place at the Malaysian Pavillion of the World Expo Osaka 2025, during the opening of 'Sustainable Agriculture Week' witnessed by The Honorable Datuk Seri Haji Mohamad bin Sabu, Minister of Agriculture and Food Security. This partnership unites two companies with a shared commitment to the development and marketing of high-quality, clinically supported herbal ingredients. With decades of industry experience, both companies are dedicated to raising the standards of natural product innovation through scientific rigor, transparency and product integrity. Physta ® Tongkat Ali, developed through a landmark collaboration between the Malaysian Government and the Massachusetts Institute of Technology (MIT), stands as one of the world's most clinically studied Tongkat Ali (Eurycoma longifolia) extracts. It is backed by over 20 clinical studies and has been shown to support energy, vitality, libido, immunity, stress management and hormonal health. Recently, new research from Biotropics has uncovered Physta ® 's efficacy in supporting hormonal balance and reducing stress in pre- and postmenopausal women—a breakthrough expansion from its earlier positioning as a male-centric supplement. This positions Physta ® as a versatile ingredient for a broader demographic, supporting both men and women in managing age-related health challenges naturally. "In light of Japan's rapidly ageing population and growing demand for preventive, plant-based health solutions, we believe Physta ® brings timely and relevant benefits," said Haliza Ramli, CEO of Biotropics Malaysia. "There is a surge of interest for Tongkat Ali globally and this collaboration reflects a mutual vision: to deliver clinically supported, high-quality herbal ingredients that meet the needs of discerning, health-conscious consumers." Koichi Hosaka, CEO and Managing Director of ASK Intercity, added, "We are excited to work with Biotropics, a globally respected leader in herbal research. Tongkat Ali is already recognized internationally, and we believe Physta ® will be very appealing to Japanese consumers seeking natural vitality, stress support, hormonal balance and even looking for Power of Malaysian original forest". The partnership arrives at a pivotal time: Japan has the world's oldest population, with over 29% aged 65 and above. As healthy ageing becomes a national priority, ingredients like Physta ® —with proven benefits and gender-inclusive applications—offer real value to brand owners formulating for this dynamic segment. The MOU aims to redefine natural wellness in one of Asia's most mature and discerning health markets and sets foundation for future cooperation between Malaysia and Japan in the field of herbal science, innovation and market development. Biotropics' portfolio—including BioKesum ®, SLP+ ®, Nu-Femme ®, and Eurecta ® —continues to expand, driven by strong IP, clinical validation and Malaysia's rich botanical heritage.
Korea Herald
a day ago
- Korea Herald
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.
